* Evolent Health Inc EVH.N EVH is expected to show a
rise in
quarterly revenue when it reports results on May 3.
* The Arlington Virginia-based company is expected to
report a
46.2% increase in revenue to $434.338 million from $297.06
million a year ago, according to the mean estimate from 10
analysts, based on Refinitiv data. The company's guidance on
February 22 2023, for the period ended March 31, was for revenue
between $420.00 million and $440.00 million.
* Refinitiv's mean analyst estimate for Evolent Health Inc
is for
earnings of 20 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Evolent
Health
Inc is $46, above its last closing price of $36.44.
The company's guidance on February 22 2023 for the period ended
March 31 was for Earnings before Interest, Taxes, Depreciation
and Amortization of between USD420 million and USD50 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 0.20 0.16 0.10 Missed -39.1
Sep. 30 2022 0.13 0.12 0.59 Beat 397.6
Jun. 30 2022 0.05 0.05 0.10 Beat 105.9
Mar. 31 2022 0.00 0.00 0.12 Beat 6,100
Dec. 0.00 0.01 0.08 Beat 860.4
31 2021
Sep. 30 2021 -0.02 -0.03 -0.03 Met 8.7
Jun. 30 2021 -0.03 -0.04 -0.02 Beat 44.4
Mar. 31 2021 -0.05 -0.06 -0.01 Beat 84.6
This summary was machine generated May 2 at 02:02 GMT. All
figures in US dollars unless otherwise stated